Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5603316 | 0.74 | CYP1A2 (0.37) | TRPA1AXLKIF11NOTUMPSMB8 | |
| SCHEMBL311435 | 0.73 | TRPA1 (0.55) | TRPA1MEN1MAPTHTTKMT2A | |
| SCHEMBL1772874 | 0.73 | TRPA1 (0.55) | TRPA1MEN1MAPTHTTKMT2A | |
| SCHEMBL9232229 | 0.73 | TRPA1 (0.55) | TRPA1MEN1MAPTHTTKMT2A | |
| SCHEMBL1772872 | 0.73 | TRPA1 (0.55) | TRPA1MEN1MAPTHTTKMT2A | |
| SCHEMBL29893783 | 0.69 | TRPA1 (0.50) | TRPA1MEN1MAPTHTTKMT2A | |
| SCHEMBL1343228 | 0.69 | TRPA1 (0.53) | TRPA1MEN1MAPTHTTKMT2A | |
| Dibenzo[B,F][1,4]Oxazepine SCHEMBL123289 | 0.67 | TRPA1 (1.00) | TRPA1MEN1MAPTHTTKMT2A | |
| SCHEMBL15011058 | 0.67 | AXL (0.34) | KMT2AAXLKIF11CYP1A2CYP2D6 | |
| Dibenzo[B,F][1,4]Oxazepine SCHEMBL30601896 | 0.66 | TRPA1 (0.96) | TRPA1MEN1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021119183-A1 | TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES | 712 NORTH, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-7517871-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060199798-A1 | Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | EK FREDRIK | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199798-A1 | Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | OPRL1, CHRM4, CNR1 | TRPA1 1239/4885MEN1 3032/4885MAPT 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.